BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20534033)

  • 1. Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management.
    Veroux M; Corona D; Giuffrida G; Cacopardo B; Sinagra N; Tallarita T; Giaquinta A; Zerbo D; Veroux PF
    Transpl Infect Dis; 2010 Oct; 12(5):387-91. PubMed ID: 20534033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral leishmaniasis after renal transplantation: report of 4 cases in northeastern Brazil.
    Oliveira RA; Silva LS; Carvalho VP; Coutinho AF; Pinheiro FG; Lima CG; Leandro JE; Silva GB; Daher EF
    Transpl Infect Dis; 2008 Oct; 10(5):364-8. PubMed ID: 18507750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case.
    Postorino MC; Bellantoni M; Catalano C; Caridi G; De Rosa M; Seck S; Enia G
    J Nephrol; 2011; 24(4):530-4. PubMed ID: 21607915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis in renal transplant recipients: clinical aspects, diagnostic problems, and response to treatment.
    Oliveira CM; Oliveira ML; Andrade SC; Girão ES; Ponte CN; Mota MU; Fernandes PF; Campos HH; Esmeraldo RM; Evangelista JB
    Transplant Proc; 2008 Apr; 40(3):755-60. PubMed ID: 18455008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral leishmaniasis: a rare cause of post-transplant fever and pancytopenia.
    Rajaram KG; Sud K; Kohli HS; Gupta KL; Sakhuja V
    J Assoc Physicians India; 2002 Jul; 50():979-80. PubMed ID: 12126362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk factors for and effects of visceral leishmaniasis in graft and renal transplant recipients.
    Alves da Silva A; Pacheco-Silva A; de Castro Cintra Sesso R; Esmeraldo RM; Costa de Oliveira CM; Fernandes PF; Oliveira RA; Silva LS; Carvalho VP; Nery Costa CH
    Transplantation; 2013 Mar; 95(5):721-7. PubMed ID: 23388734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
    Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis after kidney transplantation: report of a new case and a review of the literature.
    Bouchekoua M; Trabelsi S; Ben Abdallah T; Khaled S
    Transplant Rev (Orlando); 2014 Jan; 28(1):32-5. PubMed ID: 24321305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).
    Pagliano P; Rossi M; Rescigno C; Altieri S; Coppola MG; Gramiccia M; Scalone A; Gradoni L; Faella F
    J Antimicrob Chemother; 2003 Aug; 52(2):264-8. PubMed ID: 12865389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis in a renal transplant recipient treated with allopurinol.
    Harzallah K; Belhadj R; Jemli B; Haloues M; Berraies N; Gargouri S; Hmida J; Battikh R; Manaa J
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):105-8. PubMed ID: 20061702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study.
    Clemente W; Vidal E; Girão E; Ramos AS; Govedic F; Merino E; Muñoz P; Sabé N; Cervera C; Cota GF; Cordero E; Mena A; Montejo M; López-Medrano F; Aguado JM; Fernandes P; Valerio M; Carratalá J; Moreno A; Oliveira J; Mourão PH; Torre-Cisneros J
    Clin Microbiol Infect; 2015 Jan; 21(1):89-95. PubMed ID: 25636932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B.
    Tavil B; Seçmeer G; Ozen H; Cengiz AB; Unal S; Gürgey A
    Turk J Pediatr; 2008; 50(1):67-9. PubMed ID: 18365595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral Leishmaniasis in Renal Transplant Recipients: Report of 2 Cases.
    Clavijo Sánchez F; Vázquez Sánchez T; Cabello Díaz M; Sola Moyano VE; Jironada Gallego C; Hernández Marrero D
    Transplant Proc; 2018 Mar; 50(2):581-582. PubMed ID: 29579858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated diagnosis and graft involvement for visceral leishmaniasis in kidney transplant recipients: a case report and literature review.
    Busutti M; Deni A; De Pascali AM; Ortalli M; Attard L; Granozzi B; Fabbrizio B; La Manna G; Comai G; Varani S
    Infection; 2023 Apr; 51(2):507-518. PubMed ID: 36329343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases.
    de Silva AA; Pacheco e Silva Filho Á; Sesso Rde C; Esmeraldo Rde M; de Oliveira CM; Fernandes PF; de Oliveira RA; de Silva LS; de Carvalho VP; Costa CH; Andrade JX; da Silva DM; Chaves RV
    BMC Infect Dis; 2015 Feb; 15():96. PubMed ID: 25877483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
    Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral leishmaniasis after orthotopic liver transplantation: a rare cause of infection.
    Pereira CM; Oliveira HM; Lopes V; Gandara J; Ferreira S; Daniel J; Miranda HP
    Transpl Infect Dis; 2016 Apr; 18(2):251-4. PubMed ID: 26895697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.
    Cuellar-Rodriguez J; Avery RK; Lard M; Budev M; Gordon SM; Shrestha NK; van Duin D; Oethinger M; Mawhorter SD
    Clin Infect Dis; 2009 Sep; 49(5):710-6. PubMed ID: 19635026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.